Key Highlights
- Hemab Therapeutics shares fell 1.54% to $38.90 despite presenting positive Phase 1 first-in-human data for HMB-002 at ISTH 2026.
- The data demonstrated proof of mechanism, with dose-dependent, greater-than-2.4-fold peak increases in VWF and FVIII levels.
- Results also showed normalization of peak thrombin generation and activated partial thromboplastin time (APTT), with durability supporting potential monthly subcutaneous dosing.
- Despite the encouraging early-stage data, Hemab carries a substantial market capitalization of approximately $1.82 billion, suggesting today's modest pullback reflects normal trading volatility rather than a negative reassessment of the program.
Hemab Therapeutics Holdings Inc. (NASDAQ: COAG) shares fell 1.54% to $38.90 today, a modest pullback that comes despite the company presenting encouraging Phase 1 first-in-human data for its lead candidate HMB-002 at the International Society on Thrombosis and Haemostasis (ISTH) 2026 meeting, as part of its VELORA Discover clinical program in Von Willebrand Disease.
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, caused by deficient or dysfunctional von Willebrand factor (VWF), a protein essential for normal blood clotting. Patients with VWD can experience excessive bleeding, and current treatment options often require frequent administration, making a therapy with the potential for durable, less frequent dosing a meaningful area of unmet need within the rare disease and hematology space.
The Phase 1 data presented at ISTH demonstrated clear proof of mechanism for HMB-002, showing dose-dependent, greater-than-2.4-fold peak increases in both VWF and Factor VIII (FVIII) levels — the two key clotting factors implicated in VWD pathology. This kind of dose-dependent response is an important early validation that the drug is engaging its intended biological target in the expected direction.
Beyond the factor level increases, the data also showed normalization of peak thrombin generation and activated partial thromboplastin time (APTT), both standard laboratory measures used to assess blood clotting function. Normalization of these parameters suggests HMB-002 is not just increasing factor levels numerically, but translating that increase into functionally normalized clotting activity, a more clinically meaningful signal than factor level increases alone.
Perhaps most notably for the drug's commercial and clinical potential, the data showed durability supporting potential monthly subcutaneous dosing. A monthly, self-administered subcutaneous dosing regimen would represent a significant convenience improvement over more frequent treatment options, a factor that could meaningfully differentiate HMB-002 if these results are confirmed in later-stage trials.
Given the clearly positive nature of this Phase 1 data readout, today's modest 1.54% decline likely reflects routine trading volatility rather than any negative reassessment of the program, particularly for a company carrying a substantial market capitalization of approximately $1.82 billion. Investors will likely look for continued dose-escalation and expanded patient data from the ongoing VELORA Discover program as the next steps in HMB-002's development toward later-stage trials in Von Willebrand Disease.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...